These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [New pharmacodynamic effects of gidazepam and befol in patients with cardiac arrhythmias]. Skibitskiĭ VV; Kanorskiĭ SG Eksp Klin Farmakol; 1993; 56(5):23-7. PubMed ID: 7906171 [TBL] [Abstract][Full Text] [Related]
9. I(Kr) vs. I(Ks) blockade and arrhythmogenicity in normoxic rabbit Purkinje fibers: does it really make a difference? Puddu PE; Legrand JC; Sallé L; Rouet R; Ducroq J Fundam Clin Pharmacol; 2011 Jun; 25(3):304-12. PubMed ID: 21241363 [TBL] [Abstract][Full Text] [Related]
10. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo. Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834 [TBL] [Abstract][Full Text] [Related]
11. Dofetilide: a new class III antiarrhythmic agent. Al-Dashti R; Sami M Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents. Phillips GB; Morgan TK; Lumma WC; Gomez RP; Lind JM; Lis R; Argentieri T; Sullivan ME J Med Chem; 1992 Feb; 35(4):743-50. PubMed ID: 1347318 [TBL] [Abstract][Full Text] [Related]
13. Dofetilide: a class III-specific antiarrhythmic agent. Kalus JS; Mauro VF Ann Pharmacother; 2000 Jan; 34(1):44-56. PubMed ID: 10669186 [TBL] [Abstract][Full Text] [Related]
14. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Singh SN Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718 [TBL] [Abstract][Full Text] [Related]
15. Dofetilide: a new class III antiarrhythmic agent. Roukoz H; Saliba W Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453 [TBL] [Abstract][Full Text] [Related]
16. [Progress in the clinical use of anti-arrhythmic drugs (I)]. Li WZ Zhonghua Er Ke Za Zhi; 2003 Oct; 41(10):735-7. PubMed ID: 14731351 [No Abstract] [Full Text] [Related]
17. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Orth PM; Hesketh JC; Mak CK; Yang Y; Lin S; Beatch GN; Ezrin AM; Fedida D Cardiovasc Res; 2006 Jun; 70(3):486-96. PubMed ID: 16545351 [TBL] [Abstract][Full Text] [Related]
18. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331 [TBL] [Abstract][Full Text] [Related]
19. Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients. McCauley M; Vallabhajosyula S; Darbar D Card Electrophysiol Clin; 2016 Jun; 8(2):481-93. PubMed ID: 27261836 [TBL] [Abstract][Full Text] [Related]
20. Dofetilide, a novel class III antiarrhythmic agent. Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]